A while ago, I started a thread titled "Lessons Learned" where I was speculating that ACTC investors could possibly learn some lessons from what has happened to GERN over the past 10-15 years.
Some current points to ponder:
1. GERN has OVER 500 patents or patent pendings yet its PPS is under $5!
2. GERN PPS spiked a little at the announcement of the first human injection in Oct'10.
3. GERN has NOT announced any progress on the first patient or whether a second or third has been injected.
4. GERN announced a secondary shortly after the first injection which lead to multiple investor lawsuits.
5. GERN fired their CEO.
6. GERN's PPS just can't seem to get any MO MO going.
Could ACTC's management learn from GERN? I think so!!!!!
The point of this post?
PATENT ANNOUNCEMENTS APPEAR TO HAVE LITTLE EFFECT ON THE PPS! INVESTORS WANT HUMAN RESULTS NOT PROMISES!!!!
Just something to think about as we wait for the announcement of the first ACTC human injection.
digger: thanks for the input!
I'll have to remember the 1.7 billion metric.
In any case, I'm optimistic that we will see a PPS jump when the first injection is announced.
We can anticipate, from our knowledge of technical analysis, that they gap will be filled.
Maybe a GREAT time for some swing trading?
If ACTC's PPS goes to $5 (right around where GERN is), I don't think anyone here would mind.
Injections will be late May early June. By the time my birthday comes around, July 30, the PPS should be significantly higher, and we will be hearing about some results.
Think Market Cap for comparison, .40 would put ACTC on par with GERN in regards to Market Capacity (Shares x PPS)
GERN has 128 Million shares
ACTC has 1.5 Billion
Can ya get the difference? No, probably not.
One more thing, "hearing about some results" Let's not miss the obvious puns, "Seeing some results", duh.
super: GERN's outstanding stock is about 120 Million shares.
As I understand it, ACTC is something like 1.2 Billion.
So, there is something like a 10:1 difference.
GERN's $4.73 would be like $1.63 for ACTC.
Just a rough comparison.
With postitive human results, I could see ACTC going way past GERN unless GERN reports some success.
Yes, but GERN is doing trials on the spine which is a lot more complicated and harder to show improvements, where ACTC is working on the eyes, which is less physically complicated and easier to "see" results. When the patients in the trials say they can "see" again, it will be hard to hold this back when news of this starts to leak.
In a way you are correct.
This is the difference!
GERN----LONGER TERM FOR RESULTS BECAUSE OF THE SEVERITY OF THE INJURY.
ACTC----VERY UNIQUE... RPE CELLS TAKES ONLY SEVERAL WEEKS ON OR BEFORE THE 6TH WEEK. YOU WILL SEE RESULTS...THAT IS WHY I INVESTED IN THIS COMPANY!!
The safety concerns with the Geron injections will take much longer to sort out. Lanza reassures us that it will be less than six months for any safety issues to be addressed. Injections by June, safety by December. SS
Twelve people left almost blind by a hereditary condition that strikes in childhood are to receive the world's first eye therapy derived from human embryonic stem cells (hESCs).
The treatment is for Stargardt's macular dystrophy, which affects 1 in 8000 people in the US. Their sight deteriorates from around age 6 when retinal pigment epithelial cells (RPEs) start to die off rapidly, possibly due to a defective gene. Without RPEs to support and nourish them, adjacent photoreceptor cells which capture light signals, die too and blindness is the result.
People in the trial will be those whose vision has deteriorated to the point where they can see the movement of their own hand, but little else. They will receive injections into their eyes of between 50,000 and 200,000 RPEs.
"The goal is to halt the rate of photoreceptor loss," says Robert Lanza, chief scientist at Advanced Cell Technology (ACT) of Worcester, Massachusetts, the company that has been developing the treatment since first turning hESCs into RPEs in 2004. By implanting new RPEs, which do not contain the defective gene, the team hopes to prevent further deterioration or perhaps even reverse it.
Vision in six months
"We will hopefully show safety, and we may be able to see improvements in vision in as little as six months," says Lanza.
It will be relatively easy for the team to monitor the fate of the new cells because they can be seen in the eye through a microscope. They can also be removed if there are any adverse effects.